Reversal of aberrant cancer methylome and transcriptome upon direct reprogramming of lung cancer cells

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Mahalingam, Dashayini ^a   Kong, Chiou Mee ^a   Lai, Jason ^a   Tay, Ling Lee ^a   Yang, Henry ^b   Wang, Xueying ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; CELL DIFFERENTIATION; CLUSTER ANALYSIS; CPG ISLAND; CYTOLOGY; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PROMOTER REGION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CARCINOGENS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; CELL LINE, TUMOR; CLUSTER ANALYSIS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LUNG NEOPLASMS; NUCLEAR REPROGRAMMING; PROMOTER REGIONS, GENETIC; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84866118030     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00592     Document Type: Article

References (56)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011).
2. Duesberg, P., Fabarius, A. & Hehlmann, R. Aneuploidy, the primary cause of the multilateral genomic instability of neoplastic and preneoplastic cells. IUBMB Life 56, 65-81 (2004). (Pubitemid 38418923)
3. Esteller, M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16 Spec No 1, R50-59 (2007). (Pubitemid 47241842)
4. Adjei, A. A. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93, 1062-1074 (2001). (Pubitemid 32717538)
5. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000). (Pubitemid 30046295)
6. Boveri, T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci 121 Suppl 1, 1-84 (2008).
7. Natarajan, A. T. DNA repair and human disease 61 (Landes Bioscience 2006).
8. Duesberg, P.,Mandrioli, D.,McCormack, A. & Nicholson, J. M. Is carcinogenesis a form of speciation? Cell Cycle 10, 2100-2114 (2011).
9. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007). (Pubitemid 350138099)
10. Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920 (2007).
11. Colman, A. & Dreesen, O. Pluripotent stem cells and disease modeling. Cell Stem Cell 5, 244-247 (2009).
12. Devine, M. J. et al. Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat Commun 2, 440 (2011).
13. Allegrucci, C. et al. Epigenetic reprogramming of breast cancer cells with oocyte extracts. Mol Cancer 10, 7 (2011).
14. Miyoshi, N. et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A 107, 40-45 (2010).
15. Utikal, J., Maherali, N., Kulalert, W. & Hochedlinger, K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 122, 3502-3510 (2009).
16. Polo, J. M. et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 28, 848-855 (2010).
17. Chin, M. H. et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5, 111-123 (2009).
18. Bock, C. et al. Reference Maps of human ES and iPS cell variation enable highthroughput characterization of pluripotent cell lines. Cell 144, 439-452 (2011).
19. Deaton, A. M. & Bird, A. CpG islands and the regulation of transcription. Genes Dev 25, 1010-1022 (2011).
20. Mohn, F. et al. Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell 30, 755-766 (2008).
21. Suzuki, M. et al. Aberrant methylation of Reprimo in lung cancer. Lung Cancer 47, 309-314 (2005). (Pubitemid 40248735)
22. Hou, J. et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 5, e10312 (2010).
23. Hirashima, T. et al. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 18, 4713-4716 (1998). (Pubitemid 29042049)
24. Arumugam, T. & Logsdon, C. D. S100P: a novel therapeutic target for cancer. Amino Acids 41, 893-899 (2011).
25. Flanagan, J. M. et al. Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets. Mol Cancer Ther 8, 249-260 (2009).
26. Wang, K. K. et al. Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene 21, 7598-7604 (2002).
27. Camilo, R., Capelozzi, V. L., Siqueira, S. A. & Del Carlo Bernardi, F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol 37, 542-546 (2006).
28. Higgins, M. E., Claremont, M.,Major, J. E., Sander, C. & Lash, A. E. CancerGenes: a gene selection resource for cancer genome projects. Nucleic Acids Res 35, D721-726 (2007). (Pubitemid 46056298)
29. Nojiri, K. et al. The proangiogenic factor ephrin-A1 is up-regulated in radioresistant murine tumor by irradiation. Exp Biol Med (Maywood) 234, 112-122 (2009).
30. Hatfield, K. J., Bedringsaas, S. L., Ryningen, A., Gjertsen, B. T. & Bruserud, O. Hypoxia increases HIF-1alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. Eur Cytokine Netw 21, 154-164 (2010).
31. Keeley, E. C.,Mehrad, B. & Strieter, R. M. CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 106, 91-111 (2010).
32. Cheng, Y. J. et al. Id1 promotes lung cancer cell proliferation and tumor growth through Akt-related pathway. Cancer Lett 307, 191-199 (2011).
33. Nowacki, S. et al. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma. Oncogene 27, 3329-3338 (2008). (Pubitemid 351733395)
34. Jarmalaite, S. et al. Tumor suppressor gene ZAC/PLAGL1: altered expression and loss of the nonimprinted allele in pheochromocytomas. Cancer Genet 204, 398-404 (2011).
35. Hong, H. et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460, 1132-1135 (2009).
36. Hochedlinger, K. et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 18, 1875-1885 (2004). (Pubitemid 39025097)
37. Lin, S. L. et al.Mir-302 reprograms human skin cancer cells into a pluripotent EScell- like state. RNA 14, 2115-2124 (2008).
38. Carette, J. E. et al. Generation of iPSCs from cultured human malignant cells. Blood 115, 4039-4042 (2010).
39. Mathieu, J. et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71, 4640-4652 (2011).
40. Ron-Bigger, S. et al. Aberrant epigenetic silencing of tumor suppressor genes is reversed by direct reprogramming. Stem Cells 28, 1349-1354 (2010).
41. Helman, E., Naxerova, K. & Kohane, I. S.DNAhypermethylation in lung cancer is targeted at differentiation-associated genes. Oncogene 31, 1181-1188 (2012).
42. Liu, H., Kho, A. T., Kohane, I. S. & Sun, Y. Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development. PLoS Med 3, e232 (2006).
43. Naxerova, K. et al. Analysis of gene expression in a developmental context emphasizes distinct biological leitmotifs in human cancers. Genome Biol 9, R108 (2008).
44. Landi, M. T. et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 3, e1651 (2008).
45. Bild, A. H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006). (Pubitemid 43128862)
46. Fingleton, B. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects. Expert Opin Ther Targets 7, 385-397 (2003). (Pubitemid 36722223)
47. Tweardy, D. & Chang, J. C. Stat5: from breast development to cancer prognosis, prediction, and progression. J Clin Oncol 29, 2443-2444 (2011).
48. Kuhn, T. S. The structure of scientific revolutions (University of Chicago Press, 1996).
49. Yoo, C. B.& Jones, P.A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5, 37-50 (2006).
50. Du, P., Kibbe, W. A. & Lin, S. M. lumi: a pipeline for processing Illumina microarray. Bioinformatics 24, 1547-1548 (2008). (Pubitemid 351911712)
51. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3,Article3 (2004).
52. team, R. d. c. R: A language and environment for statistical computing. R foundation for statistical computing. (2011).
53. Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193 (2003). (Pubitemid 36181903)
54. Du, P. et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11, 587 (2010).
55. Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37, 1-13 (2009).
56. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57 (2009).